Gastric Cancer
Conditions
Keywords
chemotherapy, surgery, Surgically-Created Resection Cavity, Adverse Reaction to Drug
Brief summary
Explore the hyperthermic intraperitoneal chemotherapy (HIPEC) and intravenous chemotherapy for Creating the Operation Chance in advanced gastric cancer with peritoneal metastasis.
Detailed description
To assess the effectiveness and safety of Hyperthermic intraperitoneal chemotherapy, intravenous chemotherapy combined with surgery for the treatment of advanced gastric cancer with peritoneal metastasis,so as to further find out the optimal protocol for the Conversion therapy in the patients with advanced gastric cancer.
Interventions
OTHERHIPEC,Chemotherapy AND surgery
1. HIPEC（RHL-2000B, Madain Medical Devices Co., Ltd., Jilin, China): Taxol (Paclitaxel Injection) 75 mg/m2, twice, within 72 hours after surgical exploration ; oral chemotherapy:S-1(Tegafur,Gimeracil and Oteracil Potassium Capsules): 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week. 2. chemotherapy(PS for 3 cycles) : Taxol 150mg/m2,d1, S-1: 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week. 3. surgery:Secondary surgical exploration:if PCI less than 20,then perform the cytoreductive surgery(resection of primary tumors and metastases ) 4. after the surgery,HIPEC for two cycles,and PS chemotherapy for 3 cycles
Sponsors
Zhejiang Cancer Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
gastric cancer confirmed by endoscopic biopsy , and enhanced CT suspected to have peritoneal metastasis, including ascites, ovarian metastasis, omentum or peritoneal metastasis. * Definitely diagnosed as above stage of stomach cancer before the operation via CT or MRI, ultrasonic endoscopy and blood tumor antigen test, or through the laparoscopy if necessary * Untreated (e.g. radiotherapy, chemotherapy, target therapy and immunotherapy) * ECOG (Eastern Cooperative Oncology Group) : 0\ 2 * Age: 18\ 75 years old * Normal hemodynamic indices before the recruitment (including blood cell count and liver/kidney function). For example: WBC\>4.0×109/L, NEU \>1.5×109/L, PLT\>100×109/L, BIL\<1.5 times of upper limit of normal reference value, ALT and AST\<2.5 times of upper limit of normal reference value, and CRE\<1.2mg/dl * Good cardiac function before the recruitment, no seizure of myocardial infarction in past half year, and controllable hypertension and other coronary heart diseases * Not concomitant with other uncontrollable benign diseases before the recruitment (e.g. the infection in the lung, kidney and liver) * Not participating in other study projects before and during the treatment * Signed the Informed Consent Form
Exclusion criteria
* Not conforming to above inclusion criteria * Distal metastasis to lung, liver, or para aortic lymph node metastasis * Ever operation on the stomach * Operation intolerance due to other systemic basic diseases * Ever administered other drugs (including TCM drugs) before the recruitment, or no guarantee of progress according to the study requirement after the recruitment * Allergy to the drugs in this protocol * Pregnant or lactating women * Women at childbearing age and of pregnancy desire during the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| R0 resection | 3 months | the rate of R0 resection |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Events | 6 months | Number and degree of Adverse Events |
| Overall survival time | 3 years | the overall survival time |
Countries
China
Contacts
Primary ContactYian Du, MD
Backup ContactPengfei Yu, MD
Outcome results
None listed